Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)
Cathomas, R Crabb, S Kenner, H Mark, M Rothermundt, C Winterhalder, R Von Burg, P Vilei, S Hayoz, S
Cathomas, R
Crabb, S
Kenner, H
Mark, M
Rothermundt, C
Winterhalder, R
Von Burg, P
Vilei, S
Hayoz, S
Citations
Altmetric:
Abstract
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). 2015, 51 S473-S473 Eur J Cancer